GI Innovation KRX:358570KOSDAQ
지아이이노베이션 · Korean news coverage and regulatory filings, organized.
In Q3 2026, GI Innovation reported an operating loss of ₩15.7bn. GI Innovation (지아이이노베이션) appeared in 9 Korean news articles and 5 DART filings over the past seven days. Coverage peaked on Nov 5 with 9 articles. The most common catalyst was contracts & orders (2). It was most often mentioned alongside 글로벌테크놀로지, Curocell and Y-Biologics.
Filing signals Insider buying Clinical trial filing 4 quarters of losses Share pledge Screener
GI Innovation at a glance from DART filings
- Results trend
- Operating loss in each of the last 4 quarters; Q3 2026 operating loss of ₩16bn a loss again after the previous quarter.
- Ownership changes
- 14 5%-holder and insider ownership reports in the past 120 days (12 increases, 1 decreases).
Figures the company filed on DART, grouped by ATS View. Not a buy or sell call; see the cards below and the DART originals.
GI Innovation today: up or down?
No sign-up, one tap a day. These numbers show what visitors think and are not investment advice.
Upcoming dates as filed
- Mar 31 Annual report filing deadlinein 134 days · period ending Dec 2026
Dates GI Innovation stated in its DART filings. A conversion period opening does not mean new shares appear that day; bondholders must request conversion.
GI Innovation quarterly results separate, KRW
| Quarter | Operating profit | Net income |
|---|---|---|
| Q3 2026 | −₩15.7bn | −₩14.9bn |
| Q2 2026 | −₩14.4bn | −₩14.3bn |
| Q1 2026 | −₩12.4bn | −₩12.3bn |
| Q4 2025 derived | −₩7.2bn | −₩3.1bn |
| Q3 2025 | −₩10.7bn | −₩9.5bn |
| Q2 2025 | −₩10.9bn | −₩9.8bn |
| Q1 2025 | −₩11.8bn | −₩12.8bn |
| Q4 2024 derived | −₩12.2bn | −₩20.0bn |
GI Innovation ranks #2309 of 2,345 Korean listed companies by Q3 2026 operating profit. Q3 2026 Korean earnings rankings →
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
GI Innovation top stories 2 weeks, by number of outlets
- 1
- 2
- 3
- 4
- 5
- 6
Latest GI Innovation news Korean headlines
-
GI Innovation participates in Europe's largest healthcare investment conference 'Jefferies London'
2 more on this story · 2 outlets
-
GI Innovation administers first patient in GI-102 and J&J cancer drug combination clinical trial
2 more on this story · 2 outlets
-
GI Innovation and Trioer sign business agreement on next-generation masking multi-antibody joint development
2 more on this story · 2 outlets
-
GI Innovation to present 'GI-102' subcutaneous injection clinical results at 'ESMO IO 2026'
3 more on this story · 3 outlets
- GI Innovation presents GI-102 subcutaneous injection phase 1 results at ESMO IO한국경제 · Oct 28 08:20
- GI Innovation discloses GI-102 subcutaneous injection clinical results바이오타임즈 · Oct 28 08:25
- GI Innovation presents GI-102 subcutaneous injection phase 1 clinical results at international conference뉴스1 · Oct 28 08:47